Skip to main content
logo
Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
13.68
-0.20 (-1.44%)
Aug 12, 2026, 12:37 PM EDT - Market open

Kazia Therapeutics Income Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Revenue
-0.042.31--15.18
Revenue Growth
--98.19%----
Gross Profit
-0.042.31--15.18
Selling, General & Admin
16.448.7213.568.585.247.02
Research & Development
10.537.3317.3815.5620.1714.54
Other Operating Expenses
1.915.170.1700.030
Total Operating Expenses
28.8731.2131.1224.1525.4321.56
Operating Income
-28.87-14.15-28.81-24.15-25.43-6.38
Interest Income
0.280.070.010.0200.04
Other Non-Operating Income (Expense)
1.125.081.43.39--2.57
Total Non-Operating Income (Expense)
1.45.151.413.410-2.53
Pretax Income
-30.68-22.45-27.05-20.74-25.38-8.9
Provision for Income Taxes
-1.61-1.75-0.27-0.27-0.37-0.48
Net Income
-29.07-20.7-26.78-20.47-25.01-8.42
Net Income to Common
-29.07-20.7-26.78-20.47-25.01-8.42
Net Income Growth
------
Shares Outstanding (Basic)
011000
Shares Outstanding (Diluted)
011000
Shares Change
-82.59%107.81%43.08%39.12%12.57%61.08%
EPS (Basic)
-32.23-18.90-50.80-56.15-94.40-35.80
EPS (Diluted)
-32.23-18.90-50.80-56.15-94.40-35.80
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Free Cash Flow
-13.04-8.78-6.39-10.1-15.7-6.83
Free Cash Flow Growth
------
Free Cash Flow Per Share
-68.31-8.01-12.12-27.40-59.26-29.03
Gross Margin
-100.00%100.00%--100.00%
Operating Margin
--33870.10%-1248.18%---42.02%
Profit Margin
--49567.60%-1160.23%---55.46%
FCF Margin
--31968.80%-415.12%---60.01%
EBITDA
-19.52-8.69-17.98-14.84-16.25-3.84
EBITDA Margin
--31632.10%-1167.20%---33.69%
EBIT
-28.87-14.15-28.81-24.15-25.43-6.38
EBIT Margin
--33870.10%-1248.18%---42.02%
Effective Tax Rate
5.13%7.78%1.00%1.31%1.45%5.44%
SEC Filings: 10-K · 10-Q